Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 17 to 65

Using metreleptin to treat anorexia nervosa

Official title: Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain Connectivity

Run by University of Zurich · NCT06305182 · Data updated 2026-11-12

This study is testing if a hormone treatment called metreleptin can help people with anorexia nervosa improve their mood and gain weight.

Quick facts

PhasePhase 2
Study typeInterventional
Ages17 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorUniversity of Zurich
Academic / other
Locations1 site (Zurich, Canton of Zurich)
StatusRecruiting
StartedMay 31, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedJuly 29, 2026
Trial IDNCT06305182 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 17 to 65 with a current diagnosis of anorexia nervosa and specific BMI requirements.

Probably not a fit

Patients with severe psychiatric or somatic comorbidities or those currently using illicit drugs or alcohol may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of metreleptin, a synthetic form of the hormone leptin, on patients diagnosed with anorexia nervosa. It employs a double-blind, placebo-controlled design, where 50 inpatients will receive either metreleptin or a placebo for 14 days. The primary goals are to assess improvements in mood and weight, while secondary objectives include evaluating brain connectivity and various health parameters. The study aims to provide a potential pharmacological treatment for a condition that currently lacks effective medications.

Why it matters

Potential benefit: If successful, this treatment could significantly improve mood and weight in patients suffering from anorexia nervosa.

How similar studies have gone: Previous studies have shown positive effects of metreleptin in small cohorts, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Main key inclusion criteria:

* Current diagnosis of AN according to fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) confirmed with Structured Clinical Interview for DSM-5 (SCID-5)
* BMI \> 13 kg/m2; BMI ≤ 18 kg/m2; body weight ≥ 35 kg
* Hospitalisation in the Eating Disorders Unit, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital of Zurich
* Ability to understand German language
* Age range: 17 - 65 years
* Depressive symptoms: HAMD-17 ≥ 8
* Negative urine pregnancy test, non-lactating and double birth control
* Informed Consent as documented by signature

Main key exclusion criteria:

* Illicit drug intake within last month; current alcohol use disorder
* Severe psychiatric and/or severe somatic comorbidities; f. e. lifetime diagnosis of schizophrenia, bipolar disorder, inflammatory bowel disorders, diabetes mellitus, autoimmune disorders, pancreatitis, neurological disorders, cancer including lymphoma
* Acute suicidality or current serious non-suicidal self-injury

Where it's running

  • Eating Disorder Unit, Clinic of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich
    Zurich, Canton of Zurich, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.